A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer
2019 ◽
Vol 38
(4)
◽
pp. 1145-1155
◽
2015 ◽
Vol 240
(2)
◽
pp. 490-496
◽
2001 ◽
Vol 276
(50)
◽
pp. 46792-46797
◽
2006 ◽
Vol 104
(6)
◽
pp. 1266-1273
◽
2009 ◽
Vol 296
(5)
◽
pp. H1425-H1433
◽
2004 ◽
Vol 63
(11)
◽
pp. 1453-1459
◽
2015 ◽
Vol 79
(5)
◽
pp. 756-766
◽
2006 ◽
Vol 5
(8)
◽
pp. 1935-1943
◽